{"entity":{"id":"nuclearmedix","kind":"company","name":"NuclearMediX","aka":[],"tldr":"NuclearMediX is an Imperial College London spin-out making a PET scan tracer that shows neuroendocrine tumours and can be produced on simple single-use cassettes. It is also working on radioactive treatments.","summary":"NuclearMediX Limited was incorporated in England on 13 December 2024 to commercialise research from Professor Eric Aboagye's lab at Imperial College London; Aboagye and Dr Ruisi Fu (managing director) are co-founders. Its lead product, NMX-001A (FETO, [18F]FET-βAG-TOCA), is a fluorine-18 PET tracer targeting somatostatin receptor 2 (SSTR2), which the company lists as phase 2 completed, with an initial focus on neuroendocrine tumours. It is designed to be made on single-use, automation-ready cassettes for multi-site production, and the platform also lists astatine-211 (alpha) and terbium-161 (Auger electron) therapeutic programmes. The company reports completing Innovate UK's ICURe programme with a GBP 300,000 grant (2024 to 2026) and a UK production partnership near the Cambridge Biomedical Campus (March 2026).","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.nuclearmedix.com/"},{"label":"Companies House record","url":"https://find-and-update.company-information.service.gov.uk/company/16134861"},{"label":"News","url":"https://www.nuclearmedix.com/news"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":["radiopharma"],"technologies":["sstr-pet","pet-tracer-manufacturing","astatine-211-alpha-therapy"],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Incorporation date from Companies House (company 16134861). The phase 2 status of FETO is the company's statement; the underlying studies were academic work at Imperial and were not checked here. No equity financing is disclosed."],"hq":"London","country":"GB","companyType":"radiopharma","website":"https://www.nuclearmedix.com/","founded":2024,"stage":"startup","investors":[],"funding":[]},"route":"/companies/nuclearmedix/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/"},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/"},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}]}}